Facial Plastic Surgery

Beverly Hills

This month, Xeomin® (incobotulinumtoxinA) was approved by the FDA for treatment of frown lines and wrinkles in the glabellar region. Slated to be released in the Spring of 2012, Xeomin® follows Botox and Dysport to treat dynamic wrinkles (or wrinkles caused by muscle movement), which is popular in the glabella and Crow’s feet regions.

It’s too early to tell what type of results to expect and whether patients will like Xeomin® more than Botox or Dysport. We will have to wait to see what the results will be and how it will compare to its predecessors to see if it is worth having in the office.

Back to Blog


Schedule Your Consultation

Reach out and speak with a member of our dedicated staff, and take those first exciting steps on your empowering cosmetic journey today.

In Office Virtual
Contact us media
Accessibility: If you are vision-impaired or have some other impairment covered by the Americans with Disabilities Act or a similar law, and you wish to discuss potential accommodations related to using this website, please contact our Accessibility Manager at (888) 417-8101.
Contact Us